Using plasma ctDNA methylation to guide adjuvant chemotherapy for high-risk T3N0 colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 randomized study enrolls patients with high-risk T3N0 (stage II) colorectal cancer who are positive for plasma ctDNA methylation one month after surgery. Eligible patients are randomized to different adjuvant chemotherapy regimens (capecitabine-based or FOLFOX-based) with the goal of comparing ctDNA clearance rates. Serial ctDNA methylation testing is used to track molecular response and prognosis, and treatment escalation is applied early for those with persistent ctDNA. The study is conducted at Fudan University Shanghai Cancer Center and focuses on whether intensified adjuvant therapy improves molecular and clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years, regardless of sex;
2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with an expected survival of \>3 months;
3. Histologically confirmed postoperative pTNM stage high-risk stage II colorectal cancer;
4. Positive ctDNA status at 1 month after surgery;
5. Expected survival of \>12 months;
6. Ability to understand and willingness to sign a written informed consent form (personally or via a legally authorized representative/guardian), indicating that the subject understands the study objectives and required procedures and agrees to participate.

Exclusion Criteria:

1. Receipt of neoadjuvant therapy prior to surgery;
2. Blood transfusion during surgery or within 2 weeks prior to surgery;
3. Pregnant or breastfeeding women, or individuals of reproductive potential who are not using adequate contraception;
4. History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer;
5. Uncontrolled primary brain tumors or central nervous system metastases, or presence of significant intracranial hypertension or neuropsychiatric symptoms;
6. Presence of severe or uncontrolled comorbidities, including but not limited to:Severe cardiac disease that remains unstable despite treatment, including myocardial infarction, congestive heart failure, unstable angina, symptomatic pericardial effusion, or unstable arrhythmia within 6 months prior to enrollment; Clearly diagnosed neurological or psychiatric disorders, including dementia or seizure disorders;Severe or uncontrolled infections;Active disseminated intravascular coagulation (DIC) or significant bleeding tendency;Significant impairment of major organ function;
7. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Guoxiang Cai
• Email: gxcaifuscc@163.com
• Phone: 86-18017312703

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Plasma ctDNA methylation-guided adjuvant chemotherapy for people with T4N0 and low‑risk stage III colorectal cancer.

  This trial will test whether using a blood test (plasma ctDNA methylation) to guide 3 vs 6 months of adjuvant chemotherapy or to switch regimens helps people with T4N0 or low‑risk stage III colorectal cancer after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562503

• Plasma ctDNA methylation–guided adjuvant chemotherapy for high-risk stage III colorectal cancer

  This trial will test whether adding bevacizumab to standard FOLFOX or CAPOX chemotherapy based on plasma ctDNA results helps adults with high-risk stage III colorectal cancer (T4N+ or T1-3N2).

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562490

• Chemo Brain Prehab for older adults with colorectal cancer

  This program tests whether an exercise-based prehabilitation plan, with or without vitamins, can reduce chemo brain and improve quality of life for adults aged 60–85 undergoing chemotherapy for colorectal cancer.

  Recruiting at 2 sites Lancaster University · Blackburn, Lancashire and 3 other locations · NCT07341217

• Combining targeted therapies for solid tumors using CDK4/6 inhibitors and anti-VEGF agents

  This study is testing if combining two cancer treatments, Palbociclib and Bevacizumab, can help people with solid tumors like colorectal, breast, and ovarian cancers feel better and respond better to treatment.

  Recruiting at 2 sites Phase 1 Lebanese University · Tripoli, North Lebanon and 1 other locations · NCT06307249

• ctDNA blood tests to guide treatment in colorectal cancer with liver metastases

  A study using blood tests that look for tumor DNA to help decide which patients with colorectal cancer that has spread to the liver need more treatment after surgery.

  Recruiting at 2 sites University Hospital, Montpellier · Montpellier and 1 other locations · NCT06287723

• Investigating dizziness and muscle weakness in older colorectal cancer patients during chemotherapy

  This study is testing whether a special exercise program and health check-ups can help older colorectal cancer patients feel less dizzy and improve their balance during chemotherapy.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT05710809

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.